Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173119 · ClinicalTrials.gov registry record
Can Quantitative MRI After cTACE Help Predict Survival ?
A clinical trial, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- 23
- Enrollment target
NCT02173119 is a clinical trial that has completed, run by Medical College of Wisconsin. The registered enrollment target is 23 participants.
The verdict
NCT02173119 has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with an oil called lipiodol. Lipiodol has a role as both drug carrier and embolic agent (a material that blocks blood flow to tumors). The lipiodol/chemotherapy mixture is injected into an artery (blood vessel) directly supplying blood to a HCC tumor. Lipiodol is made up of fat and water which can be seen on MRI. Therefore, MRI can be used to quantify the amount of lipiodol delivered to the HCC tumors. In this study, the investigators want to see if patient survival is related to the amount of lipiodol delivered to HCC tumors.
Interventions
- OTHER MRI post-TACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-03-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02173119
The ClinicalTrials.gov registry entry for NCT02173119 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MRI post-TACE is the first listed.
NCT02173119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02173119 about?
NCT02173119 is a clinical study titled "Can Quantitative MRI After cTACE Help Predict Survival ?". Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with an oil called lipiodol. ...
What is the current status of trial NCT02173119?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2014-08. Estimated completion is 2018-03-07.
What interventions are being tested in trial NCT02173119?
The interventions under investigation include: MRI post-TACE (OTHER).
Who is sponsoring clinical trial NCT02173119?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.